Varex Imaging Corp. (VREX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly results for Varex Imaging Corporation for the three and six months ended April 3, 2026. Varex designs, manufactures, and sells X-ray imaging components for medical diagnostic, radiation therapy, dental, veterinary, security, and industrial applications. The company operates through two segments: Medical and Industrial.
Key Financial Metrics
| Metric (in millions) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenues, Net | $216.0 | $212.9 | $425.6 | $412.7 |
| Gross Profit | $72.6 | $76.7 | $142.4 | $145.2 |
| Gross Margin | 33.6% | 36.0% | 33.5% | 35.2% |
| Operating Income | $14.4 | $22.1 | $29.8 | $33.3 |
| Net (Loss) Income Attributable to Varex | $(8.1) | $6.9 | $(5.8) | $6.6 |
| Diluted EPS | $(0.19) | $0.17 | $(0.14) | $0.16 |
| Cash and Cash Equivalents | $85.3 | $145.0 | $85.3 | $145.0 |
| Total Debt Outstanding (Net) | $347.6 | $367.5 | $347.6 | $367.5 |
| Operating Cash Flow (YTD) | $(17.6) | $26.1 | $(17.6) | $26.1 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 1.5% QoQ and 3.1% YTD compared to the prior year. The Medical segment grew 1.6% QoQ, while the Industrial segment grew 1.2% QoQ.
- Profitability Decline: Net income turned to a net loss of $8.1 million for the quarter (vs. $6.9 million profit prior year) and $5.8 million YTD (vs. $6.6 million profit prior year). This was primarily driven by a $9.4 million loss on debt extinguishment related to refinancing activities.
- Margin Compression: Gross margin decreased to 33.6% from 36.0% in the prior year quarter. The Medical segment margin dropped to 32.4% due to increased material costs, while the Industrial segment margin improved to 36.8%.
- Debt Refinancing: The company entered a new $490 million Credit Facility (Term Loan, Revolver, and Delayed Draw) and used proceeds to redeem all $368 million of outstanding Senior Secured Notes. This resulted in a $9.4 million one-time charge but is expected to reduce annual interest expense by over $7 million.
- Cash Flow: Operating cash flow turned negative ($17.6 million used) YTD, compared to $26.1 million provided in the prior year, largely due to increased inventory build-up ($51.9 million cash used) and the debt refinancing impact on accrued liabilities.
Guidance, Outlook, and Risks
- Outlook: Management expects the debt refinancing to lower total outstanding debt, improve financial flexibility, and reduce annual interest costs. No specific numerical guidance for future quarters was provided in this text.
- Trade and Tariffs: The company faces ongoing uncertainty regarding U.S. and Chinese tariffs. While a Supreme Court ruling invalidated certain IEEPA-based tariffs, the broader trade environment remains volatile, potentially impacting costs and customer purchasing decisions.
- MOFCOM Investigations: Investigations by China's Ministry of Commerce regarding X-ray tubes and CT tube inserts remain indefinitely suspended. If recommenced, they could negatively impact competitiveness in China.
- Legal Proceedings: Ongoing judicial proceedings in Germany regarding the VEC joint venture and disputes with the Saudi Arabia joint venture partner continue to divert management attention and incur costs.
- Backlog: Estimated total backlog as of April 3, 2026, was approximately $266 million.
Investor Verification Checklist
- Debt Extinguishment Impact: Verify the specific components of the $9.4 million loss on debt extinguishment and confirm the projected annual interest savings of >$7 million from the new Credit Facility.
- Inventory Levels: Review the $346.7 million inventory balance (up from $299.4 million) to assess the risk of future write-downs given the $51.9 million cash outflow for inventory YTD.
- Medical Segment Margins: Investigate the drivers of the 3.9 percentage point gross margin decline in the Medical segment, specifically the $7.4 million increase in material costs.
- Tariff Refund Status: Monitor the status of potential refunds for previously paid IEEPA tariffs and the company's ability to retain these amounts versus passing them to customers.
- Joint Venture Risks: Assess the potential financial impact of the ongoing legal disputes in Germany (VEC) and Saudi Arabia on future earnings and goodwill impairment risks.